Last updated on October 2016

Resveratrol for the Treatment of Non Alcoholic Fatty Liver Disease and Insulin Resistance in Overweight Adolescents


Brief description of study

The current project is designed as a 30-day pilot trial to demonstrate the safety and tolerability of resveratrol therapy in overweight adolescents to decrease liver fat, and improve insulin sensitivity to prevent type 2 diabetes.

Detailed Study Description

Pilot study of 10 overweight or obese children with MRS determined fatty liver randomized to resveratrol or placebo. Primary outcome measures include change in liver triglyceride content as determined by MRS and improvement in insulin resistance as determined by the area under the curve of glucose excursion during a 75 gram oral glucose tolerance test.

Clinical Study Identifier: NCT02216552

.

Contact Investigators or Research Sites near you

Start Over

Please choose location

View all locations

Brandy A Wicklow, MD, MSc

Children's Hospital Research Institute of Manitoba/University of Manitoba
Winnipeg, MB Canada
  Connect »